MedTrace Logo

Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

NCT06565975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2026-02-12

No results posted yet for this study

Summary

The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline treatment or second remission for acute myeloid leukemia in France.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

Oral azacitidine

As per product label, prescribed by treating physician

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-23
Primary Completion
2026-01-26
Completion
2026-01-26
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06565975 on ClinicalTrials.gov